Close Menu

NEW YORK – Array Genomics is in the midst of rolling out its microarray-based test for staging and grading bladder cancer based on urine samples. The molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.

While Array Genomics has seen some initial demand for the test, which is currently paid for out of pocket, the company is keen to support more studies that will raise the profile of the firm and its product and perhaps see it adopted into European urology guidelines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature survey finds a high level of support among scientists for former Vice President Joe Biden in the upcoming US election.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The Scientist reports the physician behind Surgisphere inactivated his medical license in one state and received one in another.

In PLOS this week: analysis of link between somatic copy number and telomere length, sequencing study of individuals with gallbladder S. Typhi colonization, and more.

Nov
11
Sponsored by
Illumina

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.